1053656-22-6

Basic information

• Product Name: 7-tert-butyl 2-ethyl 5,6-dihydroimidazo[1,2-a]pyrazine-2,7(8H)-dicarboxylate
• Synonyms: Imidazo[1,2-a]pyrazine-2,7(8H)-dicarboxylic acid, 5,6-dihydro-, 7-(1,1-dimethylethyl) 2-ethyl ester;5,6-Dihydroimidazo[1,2-a]pyrazine-2,7(8H)-dicarboxylic acid 7-tert-butyl 2-ethyl ester;5,6-Dihydro-8H-imidazo[1,2-a]pyrazine-2,7-dicarboxylic acid 7-tert-butyl ester 2-ethyl ester;Ethyl 7-Boc-5,6,7,8-tetrahydro-imidazo[1,2-a]pyrazine-2-carboxylate;7-tert-butyl 2-ethyl 5;Ethyl 7-BOC-3-broMo-5,6,7,8-tetrahydroiMidazo[1,2-a]pyrazine-2-carboxylate;Ethyl 7-(tert-Butoxycarbonyl)-3-bromo-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carboxylate;7-tert-Butyl 2-ethyl 5,6-dihydroimidazo[1,2-a]pyrazine-2,7(8H)
• CAS NO: 1053656-22-6
• Molecular Formula: C14H21N3O4
• Molecular Weight: 295.33424
• Product Categories: CHIRAL CHEMICALS
• Mol File: 1053656-22-6.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 457.679 °C at 760 mmHg
• Flash Point: 230.596 °C
• Appearance: /
• Density: 1.24
• Storage Temp.: 2-8°C
• PKA: 4.06±0.20(Predicted)
• CAS DataBase Reference: 7-tert-butyl 2-ethyl 5,6-dihydroimidazo[1,2-a]pyrazine-2,7(8H)-dicarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: 7-tert-butyl 2-ethyl 5,6-dihydroimidazo[1,2-a]pyrazine-2,7(8H)-dicarboxylate(1053656-22-6)
• EPA Substance Registry System: 7-tert-butyl 2-ethyl 5,6-dihydroimidazo[1,2-a]pyrazine-2,7(8H)-dicarboxylate(1053656-22-6)

Safety Data

• Hazardous Substances Data: 1053656-22-6(Hazardous Substances Data)

Usage

General Description

7-tert-butyl 2-ethyl 5,6-dihydroimidazo[1,2-a]pyrazine-2,7(8H)-dicarboxylate is a chemical compound with a complex molecular structure. It is a dicarboxylate ester with a bulky tert-butyl and ethyl groups attached to a dihydroimidazo[1,2-a]pyrazine ring system. 7-tert-butyl 2-ethyl 5,6-dihydroimidazo[1,2-a]pyrazine-2,7(8H)-dicarboxylate may have potential applications in pharmaceuticals and organic synthesis due to its structural features and functional groups, which could contribute to its biological activity and reactivity. However, further research and analysis are necessary to fully understand the properties and potential uses of this chemical compound.

Upstream product

• 77112-52-8 ethyl imidazo[1,2-a]pyrazine-2-carboxylate 
• 70-23-5 ethyl Bromopyruvate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 91476-82-3 tetrahydro-5,6,7,8 imidazo<1,2-a>pyrazinecarboxylate-2 d'ethyle 
• 623564-18-1 ethyl 5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carboxylate dihydrochloride 
• 623564-18-1 5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carboxylic acid ethyl ester hydrochloride 

Downstream Products

• 1608503-32-7 7-(5'-chloro-3,5-dimethyl-2,4'-bipyridin-2'-yl)-N-phenyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carboxamide 
• 1608503-33-8 7-(5'-chloro-3,5-dimethyl-2,4'-bipyridin-2'-yl)-N-(2-fluorophenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carboxamide 
• 1608503-34-9 C₂₅H₂₂ClFN₆O 
• 1608503-35-0 7-(5'-chloro-3,5-dimethyl-2,4'-bipyridin-2'-yl)-N-(4-fluorophenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carboxamide 
• 1608503-36-1 C₂₅H₂₁ClF₂N₆O 
• 1608503-42-9 phenyl 7-(5'-chloro-3,5-dimethyl-2,4'-bipyridin-2'-yl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carboxylate 
• 91476-82-3 tetrahydro-5,6,7,8 imidazo<1,2-a>pyrazinecarboxylate-2 d'ethyle 
• 1250996-70-3 tert-butyl 2-(hydroxymethyl)-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-carboxylate 
• 885281-30-1 7-(tert-butoxycarbonyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carboxylic acid 
• 1174069-07-8 ethyl 7-(tert-butoxycarbonyl)-3-chloro-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carboxylate 

Relevant articles and documents

PLASMA KALLIKREIN INHIBITORS

The present invention provides compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.

TRICYCLIC IMIDAZOLE COMPOUNDS AS INHIBITORS OF TRYPTOPHAN HYDROXYLASE

The present invention relates to compounds of the formula (I), wherein R1a, R1b, R2, R3, and X are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to thei

HEDGEHOG PATHWAY SIGNALING INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF

The hedgehog (Hh) signaling pathway is a pathway which regulates patterning, growth and cell migration during embryonic development, but in adulthood is limited to tissue maintenance and repair. Mutational inactivation of the inhibitory pathway components leads to constitutive ligand-independent activation of the Hh signaling pathway, results in cancers such as basal cell carcinoma and medulloblastoma. Ligand-dependent activation of Hh signaling is involved in prostate cancer, pancreatic cancer, breast cancer and blood cancers. Therefore, inhibition of the aberrant Hh signaling represents a promising approach toward novel anticancer therapy. The invention provides novel molecules of formula I that inhibit hedgehog pathway signaling and provides therapeutic applications for the treatment of malignancies (basal cell carcinoma, medulloblastoma, glioblastoma, non-small cell lung cancer, prostate cancer, pancreatic cancer, blood cancers, mesenchymal cancers, etc.), prevention of tumor regrowth, sensitization of radio-chemo therapies, and other diseases (inflammation, fibrosis and immune disorders).